Kura Oncology to Participate in Three Upcoming Investor Conferences
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Kura Oncology (Nasdaq: KURA) will participate in three investor conferences in March 2026: TD Cowen Health Care Conference on March 4 at 11:50 a.m. ET, Leerink Partners Global Biopharma Conference on March 10 at 10:40 a.m. ET, and Barclays Global Healthcare Conference on March 12 at 9:00 a.m. ET.
Live audio webcasts will be available in the Investors section of Kura’s website, with archived replays posted after each event.
Details
News Market Reaction – KURA
On Feb 25, the day this news came out, KURA closed 2.15% above the previous close.
Data tracked by StockTitan Argus for the Feb 25 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the following investor conferences:
TD Cowen Health Care Conference
March 4, 2026
11:50 a.m. ET / 8:50 a.m. PT
Leerink Partners Global Biopharma Conference
March 10, 2026
10:40 a.m. ET / 7:40 a.m. PT
Barclays Global Healthcare Conference
March 12, 2026
9:00 a.m. ET / 6:00 a.m. PT
Live audio webcasts will be available in the Investors section of Kura’s website at https://kuraoncology.com/, with archived replays available following all three events.
About Kura Oncology
Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI™, the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website at https://kuraoncology.com/ and follow us on X and LinkedIn.
Kura Contact
Investors and Media:
Greg Mann
858-987-4046
gmann@kuraoncology.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.